U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement View Product Photos

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Recall Reason Description
Due to detection of NDEA (N-Nitrosodiethylamine) Impurity
Company Name:
Teva Pharmaceuticals
Brand Name:
Brand Name(s)
Teva Pharmaceuticals
Product Description:
Product Description
Amlodipine/Valsartan Combination Tables and Amlopidine/Valsartan/Hydrochlorothiazide Combination Tablets

Company Announcement

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylan’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and certain industrial processes.

Amlodipine/Valsartan combination tablets and Amlodipine/Valsartan/Hydrochlorothiazide combination tablets are used for the treatment of high blood pressure. To date, Teva has not received any reports of adverse events signaling a potential link or exposure to valsartan.

Patients taking Amlodipine / Valsartan combination tablets or Amlodipine / Valsartan / Hydrochlorothiazide combination tablets are advised to continue taking their medication and to contact their pharmacist or physician for advice on alternative treatment. The risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment.

Teva Pharmaceuticals USA is notifying its distributors and customers by certified mail and is arranging for return/reimbursement of returned recalled products.  Distributors and retailers that have product that is being recalled should immediately stop distribution and quarantine any quantities remaining in their control and return the recalled product.

Customers and patients with medical-related questions, information about an Adverse Event or other questions about the Teva products being recalled should contact Teva’s Medical Information by phone at: 888-838-2872, option 3, then, option 4. Live calls are received Monday-Friday, 9:00AM-5:00PM Eastern Time with Voicemail available 24 hours/day, 7 days/week or email druginfo@tevapharm.com.

Adverse reactions or other problems experienced with the use of the products may also be reported to Teva directly at 888-838-2872 or to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Patient safety and product quality is critical to Teva. As always, Teva will continue to partner with, and regularly update, all relevant stakeholders, including regulatory authorities, to resolve

this situation. This issue is not limited to valsartan medicines manufactured and distributed by Teva. Some valsartan-containing products manufactured and distributed by other pharmaceutical companies using the same API supplier may also be affected.

Lots Under Voluntary Recall

The products that are part of this voluntary recall and listed below are packed in bottles. These lots were distributed nationwide to Teva’s Direct Accounts (Wholesale/Distributor/Retail/Repackagers/VA Pharmacy, et. al).

Lot # Exp. Date Product Description / Strength Bottle Size NDC
23X017 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X018 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X018 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X019 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X019 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X020 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X022 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X023 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X023 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X024 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
24X012 11/2018 Amlodipine and Valsartan Tablets 10 mg/160 mg 30 Count 0093-7691-56
24X012 11/2018 Amlodipine and Valsartan Tablets 10 mg/160 mg 90 Count 0093-7691-98
24X013 11/2018 Amlodipine and Valsartan Tablets 10 mg/160 mg 30 Count 0093-7691-56
25X028 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 90 Count 0093-7692-98
25X029 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X029 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 90 Count 0093-7692-98
25X030 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X031 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X032 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X035 4/2019 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X037 4/2019 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
26X036 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X038 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X039 11/2018 Amlodipine and Valsartan Tablets 30 Count 0093-7693-56
Lot # Exp. Date Product Description / Strength Bottle Size NDC
    10 mg/320 mg    
26X039 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X040 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X041 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X042 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X043 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X044 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X045 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X046 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X047 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X048 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X049 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X050 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X051 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
Lot # Exp. Date Product Description/ Strength Bottle Size NDC
18X010 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg 30 count 0093-7807-56
18X010 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg 90 count 0093-7807-98
18X011 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg 30 count 0093-7807-56
20X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg 30 count 0093-7810-56
20X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg 90 count 0093-7810-98
21X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg 30 count 0093-7038-56
21X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg 90 count 0093-7038-98
21X007 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg 30 count 0093-7038-56
22X045 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 30 count 0093-7809-56
22X045 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 90 count 0093-7809-98
22X046 02/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 30 count 0093-7809-56
22X047 02/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 30 count 0093-7809-56

 

Company Contact Information

Consumers:
Teva’s Medical Information
888-838-2872

Product Photos

  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg, 30 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg, 90 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg, 30 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg, 90 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg, 30 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg, 90 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg. 90 Tablets
  • Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg. 30 Tablets
Back to Top